EuroSIDA Study Group
The EuroSIDA study is a prospective observational cohort study tracking the long-term clinical outcomes and impact of antiretroviral drugs on people living with human immunodeficiency viruses (HIV) in Europe, initiated in the 1990s. The study includes data from 118 clinics across 39 countries, with a database of over 24,500 individuals and a unique plasma repository of over 200,000 samples. EuroSIDA is a founding member of the International Cohort Consortium of Infectious Disease (RESPOND) and collaborates with various other research initiatives. The mean age of the entire sample at follow-up was 50 years, and 73% were male. After baseline data collection, participants were followed up twice annually until 2016, when the follow-up was reduced to once annually.
Study design
Cohort - clinical, Cohort
Number of participants at first data collection
3,122 (participants)
Recruitment is ongoing
Age at first data collection
Varied (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
1994
Primary Institutions
University of Copenhagen (Københavns Universitet, KU) (Academic, Denmark)
Profile paper DOI
Funders
Bristol-Myers Squibb (BMS) (Industry, United States of America)
Danish National Research Foundation (DNRF) (Third Sector, Denmark)
European Union FP7 programmes (Government, Europe)
Gilead Sciences (Industry, United States of America)
Janssen Research & Development (Industry, United States of America)
Ongoing?
Yes
Data types collected
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- Self-completed questionnaire – online
- None
- None
- None
Engagement
Keywords
Consortia and dataset groups
